Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis

Annals of the Rheumatic Diseases

Volumn 63, Issue 12, 2004, Pages 1594-1600

  Calin, A ^a,b   Dijkmans, B A C ^c   Emery, P ^d   Hakala, M ^e   Kalden, J ^f   Leirisalo Repo, M ^g   Mola, E M ^h   Salvarani, C ⁱ   Sanmarti, R ^j   Sany, J ^k   Sibilia, J ^l   Sieper, J ^m   Van Der Linden, S ⁿ   Veys, E ^o   Appel, A M ^p   Fatenejad, S ^p  

^a Holmpatrick   (United Kingdom)

^b ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

^d LEEDS GENERAL INFIRMARY   (United Kingdom)

^e RHEUMATISM FOUNDATION HOSPITAL   (Finland)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ S MARIA NUOVA HOSPITAL   (Italy)

^j HOSPITAL CLÍNIC   (Spain)

^k LAPEYRONIE HOSPITAL   (France)

^l HÔPITAL DE HAUTEPIERRE   (France)

^m CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁿ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^o GHENT UNIVERSITY HOSPITAL   (Belgium)

^p PFIZER INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ETANERCEPT; INDOMETACIN; PLACEBO;

ACUTE HEART INFARCTION; ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INJECTION; INJECTION SITE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SPINE MOBILITY; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SPINE; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 9644266805     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.020875     Document Type: Article

References (53)

1. Braun J, Sieper J. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF therapy and other novel approaches. Arthritis Res 2002;4:307-21.
2. Will R, Edmunds L, Elswood J, Calin A. Is there sexual inequality in ankylosing spondylitis? A study of 498 women and 1202 men. J Rheumatol 1990;17:1649-52.
3. Kennedy LG, Edmunds L, Calin A. The natural history of ankylosing spondylitis: does it burn out? J Rheumatol 1993;20:688-92.
4. Ringsdal VS, Andreasen JJ. Ankylosing spondylitis-experience with a self administered questionnaire: an analytical study. Ann Rneum Dis 1989;48:924-7.
5. Ward MM. Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 1999;12:247-55.
6. Taylor AL, Balakrishnan C, Calin A. Reference centile charts for measures of disease activity, functional impairment, and metrology in ankylosing spondylitis. Arthritis Rheum 1998;41:1119-25.
7. Goodacre JA, Mander M, Dick WC. Patients with ankylosing spondylitis show individual patterns of variation in disease activity. Br J Rheumatol 1991;30:336-8.
8. Braun J, Pincus T. Mortality, course of disease, and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 2002;20:S16-22.
9. Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 1997;36:766-71.
10. Barlow JH, Wright CC, Williams B, Keat A. Work disability among people with ankylosing spondylitis. Arthritis Care Res 2001;45:424-9.
11. Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 2002;46:223-31.
12. Grom AA, Murray KJ, Luyrink L, Emery H, Passo MH, Glass DN, et al. Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum 1996;39:1703-10.
13. Boonen A. Socioeconomic consequences of ankylosing spondylitis. Clin Exp Rheumatol 2002;20:S23-6.
14. Clegg DO, Reda DJ, Weisman MH, Blackburn WD, Cush JJ, Cannon GW, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1996;39:2004-12.
15. Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondylarthropothy: a randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618-27.
16. Biasi D, Carletto A, Caramaschi P, Pacor ML, Maleknia T, Bambara LM. Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol 2000;19:114-17.
17. Roychowdhury B, Bintley-Bagot S, Bulgen DY, Thompson RN, Tunn EJ, Moots RJ. Is methotrexate effective in ankylosing spondylitis? Rheumatology (Oxford) 2002;41:1330-2.
18. Maksymowych WP. Novel therapies in the treatment of spondyloarthritis. Expert Opin Investig Drugs 2002;11:937-46.
19. Toussirot E, Lafforgue P, Boucraut J, Despieds P, Schiano A, Bernard D, et al. Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble cd8 in seronegative spondylarthropathies. Rheumatol Int 1994;13:175-80.
20. Gratacos J, Collado A, Filella X, Sanmarti R, Canete J, Llena J, et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994;33:927-31.
21. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505.
22. Canete JD, Llena J, Collado A, Sanmarti R, Gaya A, Gratacos J, et al. Comparative cytokine gene expression in synovial tissue of early rheumatoid arthritis and seronegative spondylarthropothies. Br J Rheumatol 1997;36:38-42.
23. Arend WP. The mode of action of cytokine inhibitors. J Rheumatol Suppl 2002;65:16-21.
24. Fernandez-Botran R. Soluble cytokine receptors: novel immunotherapeutic agents. Expert Opin Investig Drugs 2000;9:497-514.
25. Moreland LW, Schiff MS, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130:478-86.
26. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9.
27. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial, Lancet 2000;356:385-90.
28. German JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002;346:1349-56.
29. Flores D, Marquez J, Garza M, Espinoza LR. Reactive arthritis: newer developments. Rheum Dis Clin North Am 2003;29:37-59.
30. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in potients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75.
31. Davis JC, Woolley JM. Improvements in patient-reported outcomes for subjects with ankylosing spondylitis receiving etanercept therapy [abstract]. Ann Rheum Dis 2003;62(suppl I):252.
32. Van den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002;46:755-65.
33. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial, Lancet 2002;359:1187-93.
34. Andersen JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
35. Davis JC Jr, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spandylitis. Arthritis Rheum 2003;48:3230-6.
36. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
37. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
38. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
39. Moreland LW, Margolies G, Heck Jr LW, Saway A, Blosch C, Hanna R, et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996;23:1849.
40. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to TNF alpha blockers in ankylosing spondylitis [abstract]. Ann Rheum Dis, 2003;62, (suppl I):242.
41. Davis J, Devries T. Predicting treatment response to biologic agents in ankylosing spondylitis [abstract]. Ann Rheum Dis 2003;62(suppl I):36.
42. Braun J, Pham T, Sieper J, Davis J, Van der Linden S, Dougados M, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24.
43. Dougados M, Woolley JM, Tsuji W. Etanercept reduces fatigue in subjects with ankylosing spondylitis [abstract], Ann Rheum Dis 2003;62(suppl I):244.
44. van Tubergen A, Coenen J, Landewe R, Spoorenberg A, Chorus A, Boonen A, et al. Assessment of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum 2002;47:8-16.
45. Maksymowych WP, Breban M, Braun J. Ankylosing spondylitis and current disease-controlling agents: do they work? Best Pract Res Clin Rheumatol 2002;16:619-30.
46. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropothy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001;44:2112-17.
47. Abuzakouk M, Feighery C, Jackson J. Tumour necrosis factor blocking agents: a new therapeutic modality for inflammatory disorders. Br J Biomed Sci 2002;59:173-9.
48. Braun J, Sieper J, Breban M, Collantes-Estevez E, Davis J, Inman R, et al. Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience. Ann Rheum Dis 2002;61(suppl III):iii51-60.
49. Maksymowych WP, Jhangri GS, Lambert RG, Mallon C, Buenviaje H, Pedrycz E, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002;29:959-65.
50. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etonercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
51. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis. Arthritis Rheum 2002;46:1445-50.
52. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab on Crohn's disease. N Engl J Med 2003;348:601-8.
53. Zhou H, Buckwalter M, Boni J, Wajdula J, Fatenejad S, Raible D, et al. Pharmacokinetics (PK) of etanercept in ankylosing spondylitis (AS) patients were similar to those in rheumatoid arthritis (RA) patients [abstract]. Ann Rheum Dis 2003;62(suppl I):416.